BCa: men have worse survival than women in early-stage disease

  • Leone J & al.
  • Am J Clin Oncol
  • 28 nov. 2018

  • de Miriam Davis, PhD
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Male breast cancer (MBCa) is associated with worse OS than female BCa (FBCa) at stages I and II, and similar OS at stages III and IV.
  • Hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) disease was associated with doubled mortality risk in men vs women.

Why this matters

  • MBCa, which is increasing in incidence, may warrant more aggressive treatment at stages I and II.

Study design

  • Population-based retrospective cohort of 1187 patients with MBCa and patients with 166,054 FBCa with known HR/HER2 status in the Surveillance, Epidemiology, and End Results (SEER) database.
  • Funding: None disclosed.

Key results

  • Median follow-up was 21 months (range, 1-48 months).
  • MBCa had worse OS (85.6% vs 90.4% for FBCa; P=.0002).
    • Effect driven by worse OS at stage I (HR, 1.99; 95% CI, 1.2-3.3) and stage II (HR, 1.5; 95% CI, 1.1-2.2).
    • No OS differences at stage III and IV.
  • MBCa was more likely than FBCa to be ductal, have a higher grade, present at a more advanced stage, and more often be HR+/HER2 (each P<.0001>
  • On multivariate analysis, no OS gender differences by subtype, except for HR+/HER2+ showing worse survival in men (HR, 2.091; P=.002).

Limitations

  • Short follow-up.